Identifying the right treatment for your patients – the benefits of molecular profiling

Every patient is unique, reacting in different ways to the therapy they receive. In the context of cancer treatment, this individuality represents a particular challenge due to the molecularly heterogeneous nature of tumours, which acts to further influence treatment outcome. Effective prediction of patient response to, and side effects of, treatment is therefore only possible through a detailed molecular analysis of the patient genome (or exome) and their tumour (usually comprising genome/exome, transcriptome and proteome). Such comprehensive molecular profiling, now an affordable undertaking due to rapid progress in sequencing technologies, provides, in tandem with pathology data, a more accurate characterisation of individual tumours.

Such comprehensive molecular profiling, now an affordable undertaking due to rapid progress in sequencing technologies, provides, in tandem with pathology data, a more accurate characterisation of individual tumours. In this way, so called actionable variants, i.e. changes in the genome, transcriptome or proteome that are directly linked to treatment options can be identified.Based on this unique patient data, doctors can formulate an individualised treatment strategy that matches the right drug to the right patient, helping to reduce unnecessary drug side effects and ultimately increase the likelihood of successful outcome

Alacris Theranostics provides a range of tools for cancer genomics that will facilitate a personalised approach to cancer diagnostics and therapy.  Our cancer genomics services for clinicians provide a highly comprehensive tumour characterisation based on targeted sequencing and deep analysis of the cancer transcriptome and genome. Results are summarised in a clear and concise report supplying clinicians with the necessary information to support their treatment decisions.


Alacris Theranostics’ services:

  • Molecular profiling of tumours
  • Transcriptome analysis
  • Genome analysis
  • Actionable variants identification
  • Targeted sequencing
  • Assessment of response to therapy


Download flyer


Mouse xenograft models
Experimental characterisation of tumour response to treatment using patient derived xenograft models, offered by Experimental Pharmacology & Oncology Berlin-Buch (EPO).

EPO information flyer


Circulating tumour cells (CTC)
Assess patient response to therapy and/or recurrence of disease through diagnostic analyses of circulating tumour cells (CTC) using patented GILUPI CellCollector™ technology.

 

For further information on our cancer genomic services please contact us 


Relevant forms for patient consent and genetic testing can be downloaded from the links below: